Evidence map›Paper›PMID 35066447›Full record

ArticleComputers in biology and medicine2022

SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody.

Olaposi Omotuyi, Olujide Olubiyi, Oyekanmi Nash, Elizabeth Afolabi, Babatunji Oyinloye, Segun Fatumo, Mbang Femi-Oyewo, Suleiman Bogoro

Open access · greenAbstract read
In one paragraph

Article in Computers in biology and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Lucidenic acid A inhibits the binding of hACE2 receptor with spike protein to prevent SARS-CoV-2 invasion.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2022
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. [Strengthening the prevention and treatment of Omicron infection in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Olaposi OmotuyiInstitute for Drug Research and Development, S.E. Bogoro Center, Afe Babalola University, Ado Ekiti, Nigeria; Molecular Biology and Molecular Simulation Center (Mols&Sims), Ado Ekiti, Nigeria. Electronic address: olaposi.omotuyi@abuad.edu.ng.
Olujide OlubiyiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria.
Oyekanmi NashCentre for Genomics Research and Innovation, National Biotechnology Agency, Nigeria.
Elizabeth AfolabiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria.
Babatunji OyinloyeInstitute for Drug Research and Development, S.E. Bogoro Center, Afe Babalola University, Ado Ekiti, Nigeria.
Segun FatumoLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Mbang Femi-OyewoDepartment of Pharmaceutical Chemistry, College of Pharmacy, Afe Babalola University, Ado-Ekiti, Nigeria.
Suleiman BogoroInstitute for Drug Research and Development, S.E. Bogoro Center, Afe Babalola University, Ado Ekiti, Nigeria.
Afe Babalola University · NGLondon School of Hygiene & Tropical Medicine · GBNational Primary Health Care Development Agency · NG

Funding

H3ABioNet: a sustainable African Bioinformatics Network for H3AfricaU41HG006941 · NHGRI · UNIVERSITY OF CAPE TOWN · PI MULDER, NICOLA · 2012 to 2017
$14.8M
NHGRI NIH HHS U41 HG006941
6 · The paper itself

Abstract

SARS-CoV-2, the causative virus for COVID-19 has now super-mutated into the Omicron (Om) variant. On its spike (S) glycoprotein alone, more than 30 substitutions have been characterized with 15 within the receptor binding domain (RBD); It therefore calls to question the transmissibility and antibody escapability of Omicron. This study was setup to investigate the Omicron RBD's interaction with ACE2 (host receptor) and a SARS-CoV-2 neutralizing monoclonal antibody (mAb). In-silico mutagenesis was used to generate the Om-RBD in complex with ACE2 or mAb from the wildtype. HDOCK server was used to redock and score the mAbs in Om-RBD bound state relative to the wildtype. Stability of interaction between all complexes were investigated using all-atom molecular dynamics (MD). Analyses of trajectories showed that Om-RBD has evolved into an efficient ACE2 binder, via pi-pi (Om-RBD-Y501/ACE2-Y41) and salt-bridge (Om-RBD-K493/ACE2-Y41) interactions. Conversely, in binding mAb, it has become less efficient (Center of mass distance of RBD from mAb complex, wildtype ≈ 30 Å, Omicron ≈ 41 Å). Disruption of Om-RBD/mAb complex resulted from loose interaction between Om-RBD and the light chain complementarity-determining region residues. Omicron is expected to be better transmissible and less efficiently interacting with neutralizing convalescent mAbs with consequences on transmissibility provided other mutations within the S protein similarly promote cell fusion and viral entry.

Indexed as

Antibodies, MonoclonalCOVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2HumansMolecular Dynamics SimulationProtein BindingSpike Glycoprotein, CoronavirusACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, MonoclonalSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19Monoclonal antibody (mAbs)Omicron variantReceptor binding domain (RBD)Spike glycoprotein

Identifiers

PMID35066447
PMCPMC8739363
OpenAlexW4220720689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.